Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes: A Randomized Controlled Trial  by Ogawa, H. et al.
Abstracts
Gregory L. Moneta, MD, Section EditorD-dimer and Factor VIII are Independent Risk Factors for Recurrence
After Anticoagulation Withdrawal for a First Idiopathic Deep Vein
Thrombosis
Cosmi B, Legnani C, Cini M. Thromb Res 2008;122:610-7.
Conclusion: Elevated levels of D-dimer and factor VIII at 30  10
days after cessation of vitamin K antagonist (VKA) therapy for a first episode
of idiopathic proximal deep venous thrombosis (DVT) are independent risk
factors for recurrent venous thromboembolism (VTE).
Summary: The optimal duration of VKA therapy after a first episode
of VTE is unknown. It appears VKA extension after unprovoked VTE can
reduce the risk of recurrent VTE but at the potential price of increased
bleeding. There is therefore intense interest in stratifying patients with
idiopathic VTE with respect to risk factors that may increase rates of
recurrence. The specific objective of this study was to assess the risk of
recurrence of VTE associated with elevated D-dimer levels and factor
VIII levels after withdrawal of VKA therapy for symptomatic idiopathic
proximal VTE.
Consecutive outpatients with the first episode of idiopathic proximal
DVT were enrolled into the study after cessation of VKA therapy. At 30 
10 days after cessation of VKA therapy, levels of D-dimer (cutoff value, 500
ng/mL) and chromogenic factor VIII, as well as inherited thrombophilias
were determined. Follow-up extended for 2 years.
Overall recurrence rate of VTE was 16.4% (55 of 336; 95% confidence
interval [CI], 13%-21%). The multivariate hazard ratio for recurrence was
2.45 (95% CI, 1.24-4.99) for abnormal D-dimer and 2.76 (95% CI, 1.57-
4.85) for factor VIII 75th percentile (2.42 /mL). The values were
adjusted for age, sex, and thrombophilia. Compared with normal levels of
D-dimer and factor VIII, the multivariate hazard ratio was 4.5 (95% CI,
1.7-12.2) for normal D-dimer levels with factor VIII2.42 U/mL, and 2.7
(95% CI, 1.2-6.6) and 7.1 (95% CI, 2.8-17.6) for abnormal D-dimer with
factor VIII, respectively, below and above 2.42 U/mL.
Comment: The appropriate length of treatment with VKA therapy for
patients with idiopathic VTE is unknown. The data suggest the longer the
treatment period with VKA, the less the recurrence rates of VTE. Of course,
VKAs are associated with increased risk of bleeding and are inconvenient for
the patient. There is therefore intense interest in stratifying risk among those
patients with idiopathic VTE. This is another study that attempts to do just
that. The percentage of patients with both normal D-dimer and factor VIII
75th percentile was 37%. This implies that at least a third of patients with
idiopathic VTE have a low risk of VTE recurrence. Larger studies are
warranted to determine if the combination of factor VIII and D-dimer
analysis can be used to tailor duration of VKA therapy after idiopathic VTE.
Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction
Mauri L, Silbaugh TS, Garg P. N Engl J Med 2008;359:1330-42.
Conclusion: Treatment with drug-eluting stents in patients with acute
myocardial infarction (AMI) results in a decreased 2-year mortality rate and
a reduction in need for repeat revascularization procedures compared with
treatment of AMI with bare-metal stents.
Summary: The Massachusetts Department of Public Health in 2002
established a requirement that hospitals in that state providing interventional
cardiology services collect data on percutaneous coronary interventions
(PCIs). Data are collected by trained data collectors and are submitted
electronically to the Massachusetts Data Analysis Center. Analysis of this
data forms the basis of this study. The authors identify patients undergoing
PCI using coronary stents with an indication of AMI. Data were analyzed
from April 1, 2003, to September 30, 2004. The authors used a propensity-
score matching analysis on three patient groups: all patients with AMI, all
patients with AMI and ST-segment elevation, and all patients with AMI
without ST-segment elevation. Analysis was based on clinical, procedural,
hospital, and insurance information collected at the time of the PCI proce-
dure. Vital statistics records were used to determine risk of death in patients
receiving drug-eluting stents and those receiving bare-metal stents.
During the study, 7217 patients were treated for AMI, of which 4016
were treated with drug-eluting stents and 3201 with bare-metal stents.
Matched pair analysis showed the 2-year risk-adjusted mortality rates were
lower for drug-eluting stents among all patients with AMI (10.7% vs 12.8%,
P  .02). The 2-year risk-adjusted mortality rate was also lower among
patients with AMIwith ST-segment elevation (8.5% vs 11.6%, P .008) and
among patients with AMI without ST-segment elevation (12.8% vs 15.6%,
P  .04). Repeat revascularization rates in all groups were also significantly
reduced with drug-eluting stents.Comment: During the time of this study, patients with MI accounted
for 40% of coronary stent procedures in Massachusetts. Drug-eluting stents
appeared to reduce restenosis in the coronary circulation after stent treat-
ment. Previous studies have reported an association between restenosis and
risk of death forMI; therefore, the findings of the studymake inherent sense.
These data were observational, however, and although the authors tried to
make their groups comparable, there are potential confounding variables. In
particular, during the time of this study, drug-eluting stents were not
available in the same size ranges as non-drug-eluting stents. Small-vessel
stenting is associated with higher risks during follow-up and during the
procedure. Therefore, because the study was not randomized, treatment
choices may have been influenced by stent availability.
Superficial Venous Thrombosis: Prevalence of Common Genetic Risk
Factors and Their Role on Spreading to Deep Veins
Milio G, Siragusa S, Mina C, et al. Thromb Res 2008;123:194-9.
Conclusion:There is a high presence of genetic mutations (factor V Leiden,
prothrombin G20210A mutation, and 5,10-methylenetetrahydrofolate reduc-
tase [MTHFR C677T]) in patients with superficial venous thrombosis (SVT)
occurring in normal veins.
Summary: SVT that occurs in varicose veins is considered of low
clinical relevance because of the generally favorable outcome. SVT occurring
in so-called healthy veins represents only approximately 25% of all SVT. This
type of SVT is generally considered of greater clinical relevance because it has
been associated with various neoplastic conditions. It is also known that SVT
occurring in so-called healthy veins can progress into the deep system.
Depending on the study, propagation into deep veins is about 3% to 15%.
Genetic abnormalities of coagulation can also predispose to SVT. Less well
studied is whether the presence of a genetic coagulation abnormality occur-
ring in patients with SVT predisposes them to progression into the deep
system.
In this study the authors evaluated 107 patients with SVT and no other
obvious risk factors. They used ultrasound examinations to document
progression into the deep system and tested for the presence of factor V
Leiden, prothrombin G20210A mutation, and MTHFR C677T mutations.
In the patients with SVT in normal veins, factor V Leiden was present in
26.3% when the thrombus was limited to the superficial veins and was
present in 60% of SVT that extended into the deep system. Prothrombin
gene mutation was found in 7.9% of SVT limited to the superficial system
and in 20% where SVT progressed to the deep system. MTHFR C677T
mutation was found in 23.7% of patients with SVT limited to the superficial
system and in 40% where SVT progressed to the deep system. In patients
with SVT occurring in varicose veins, the presence of these abnormalities was
less common (6.7%, 4.4%, and 6.7% respectively). If, however, the SVT from
the varicose veins spread to the deep system, prevalence of genetic abnor-
malities was considerably higher (13.5% factor V Leiden mutation, 7.4%
prothrombin gene mutation, and 21.4% MTHFR C677T mutation).
Comment:This article paper provides guidance on which patients with
SVT should undergo a thrombophilia evaluation. Whereas patients with
SVT occurring in normal veins were previously recognized as having a
reasonably high incidence of genetic coagulation abnormalities, this report
points out that those patients who have SVT in varicose veins that extends
into the deep system have a significant prevalence of genetic abnormalities as
well. SVT patients appropriate for thrombophilia workup are those where
the SVT occurs in normal veins and those with SVT in varicose veins that
extends into the deep system.
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in
Patients with Type 2 Diabetes: A Randomized Controlled Trial
Ogawa H, Nakayama M, Morimoto T, et al. JAMA 2008;30:2134-41.
Conclusion: Low-dose aspirin as primary prevention does not reduce
the risk of cardiovascular events in patients with type 2 diabetes.
Summary: In patients with previous cardiovascular events, aspirin
therapy can serve as a secondary prevention strategy. Clinical guidelines also
recommend patients with risk factors for coronary heart disease should take
aspirin for primary prevention. However, subgroup analyses of large trials of
aspirin for primary prevention have not demonstrated significant effects in
patients with diabetes. Because these analyses were subgroup analyses, it is
possible they were underpowered to demonstrate primary prevention of
cardiovascular events with aspirin in patients with diabetes.The Japanese Primary Prevention of Atherosclerosis with Aspirin for
Diabetes (JPAD) Trial is reported here. The objective was to determine
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events in patients with type 2 diabetes. This was a multicenter, prospective,
randomized, open labeled, blinded end point trial conducted from Decem-
ber 2002 through April 2008 in 163 Japanese institutions. The study
enrolled 2539 patients with type 2 diabetes who did not have a history of
atherosclerotic disease. The median follow-up was 4.4 years. Patients in the
aspirin group were treated with 81 or 100 mg daily. Primary end points
included fatal or nonfatal stroke, fatal or nonfatal ischemic heart disease, and
peripheral arterial disease. Secondary end points were each component of the
primary end point, combinations of primary end points, and death from any
cause.
There were 154 atherosclerotic events comprising 68 events in the
aspirin group (13.6 per 1000 person-years) and 86 events in the nonaspirin
group (17.0 per 1000 person-years; hazard ratio [HR], 0.80; 95% confi-
dence interval [CI], 0.58-1.10; P  .16). The combined end point of fatal
coronary events and fatal cerebrovascular events occurred in one patient in
the aspirin group and in 10 patients in the nonaspirin group (HR, 1.10; 95%
CI, 0.01-0.79; P .0037). Death from any cause occurred in 34 patients in
the aspirin group and 38 patients in the nonaspirin group (HR, 0.90; 95%
CI, 0.57-1.14; P  .67). There was no difference in the aspirin and
nonaspirin groups for the composite of hemorrhagic stroke and significant
gastrointestinal bleeding.
Comment: It is becoming frustrating to demonstrate any means of
decreasing atherosclerotic events in patients with diabetes. Recent trials have
suggested that strictly controlling plasma glucose levels is also ineffective in
reducing cardiovascular events in patients with type 2 diabetes. Because of
the low event rate in this trial and that it was conducted on an entirely
Japanese population, it is probably too early to conclude that aspirin is
ineffective as primary preventative therapy in patients with type 2 diabetes.
Evidence is accumulating to that effect, however. See also the abstract “The
Prevention of Progression of Arterial Disease and Diabetes (POPADAD)
Trial: Factorial Randomised Placebo Controlled Trial of Aspirin and Anti-
oxidants in Patients with Diabetes and Asymptomatic Peripheral Arterial
Disease” in this month’s abstract section of Journal of Vascular Surgery.
Determinants and Time Course of the Postthrombotic Syndrome after
Acute Deep Venous Thrombosis
Kahn SR, Shrier I, Julian JA, et al. Ann Intern Med 2008;149:698-707.
Conclusion: The Villalta score at 1 month after an episode of acute deep
venous thrombosis (DVT) predicts late symptoms of the post-thrombotic
syndrome.
Summary: Post-thrombotic syndrome occurs as a consequence of
DVT and occurs despite optimal anticoagulation therapy. The authors note
that many studies have addressed the risk of recurrent thromboembolism
after DVT, but few studies identify which patients with DVT develop
post-thrombotic syndrome. In this study they attempted to determine the
frequency, time course, and predictors of post-thrombotic syndrome after
acute DVT. This was a prospective, multicenter, cohort study involving
eight Canadian hospital centers. From 2001 to 2004, 387 outpatients and
inpatients with an objective diagnosis of symptomatic DVT were recruited.
The Villalta score was used to assess patients for post-thrombotic
syndrome at 1, 4, 8, and 12 months after enrollment. The Villalta scale is a
clinical measurement of post-thrombotic syndrome that grades severity from
0 (absent) to 3 (severe) of five patient-related symptoms (pain, cramps,
heaviness, pruritus, and paresthesia) and six clinician-related clinical signs
(edema, redness, skin induration, hyperpigmentation, venous ectasia, and
pain on calf compression). A score of 5 indicates the presence of post-
thrombotic syndrome. The scale has been validated when measured against
quality of life instruments as well as anatomic and physiologic markers of
post-thrombotic syndrome. It appears to have good to excellent inter-
observer reproducibility and responds to clinical change. Mean post-
thrombotic syndrome scores and severity categories were calculated at
each interval.
At all study intervals, about 30% of patients had mild (5 to 9), 10% had
moderate (10 to 14), and 3% had severe (score 14, or ulcer) post-
thrombotic syndrome. The greater the category of post-thrombotic syn-
drome at 1 month, the stronger the predicted higher mean post-thrombotic
syndrome scores were throughout 24 months of follow-up. Additional
predictors of higher scores over time were thrombosis of the common
femoral or iliac vein (2.23 increase in score vs distal [calf] venous thrombosis;
P  .001), higher body mass index (0.14 increase in score per kg/m2; P 
.001), previous ipsilateral venous thrombosis (1.78 increase in score, P 
.001), older age (0.30 increase in score per 10-year age increase, P .011),
and female sex (0.79 increase in score; P  .020).
Comment: All the risk factors identified by the authors for an increase
in the severity of post-thrombotic syndrome and the development of post-
thrombotic syndrome, with the possible exception of female sex, are well
recognized. Unfortunately, the risk factors identified by the authors are not
likely to be modifiable. Therefore, the information presented here allows the
physician to inform the patient about his or her fate, but does not help much
in guiding treatment of the acute DVT with the hope of preventing future
post-thrombotic syndrome.The Prevention of Progression of Arterial Disease and Diabetes
(POPADAD) Trial: Factorial Randomised Placebo Controlled Trial of
Aspirin and Antioxidants in Patients with Diabetes and Asymptomatic
Peripheral Arterial Disease
Belch J, MacCuish A, Campbell I, and the Prevention of Progression of
Arterial Disease and Diabetes Study Group. BMJ 2008;337:1030-3.
Conclusion:Neither aspirin, antioxidant therapy, nor the combination
of aspirin and antioxidant therapy is useful in the primary prevention of
cardiovascular events and mortality in patients with diabetes and asymptom-
atic peripheral arterial disease (PAD).
Summary: Patients with asymptomatic PAD are six times more likely
to die from cardiovascular disease 10 years than patients without PAD
(N Engl J Med 1992;326:381-6). Aspirin as a secondary preventative
measure in patients with diabetes and cardiovascular disease is well estab-
lished. This has led to recommendations for use of aspirin as primary
preventative therapy as well; however, a meta-analysis has demonstrated no
efficacy for aspirin as a primary preventative therapy in patients with diabetes
(BMJ 2002;324:71-86). Some evidence also indicates that there is increase
in oxidative stress in patients with diabetes, with free radicals increasing
platelet aggregation and antioxidants decreasing platelet aggregation.
Based on the strength of the data for secondary prevention of cardio-
vascular events with aspirin therapy, the lack of data investigating aspirin as
primary preventative therapy, and potential effects of antioxidants in patients
with diabetes, the authors sought to study these agents in a group of patients
with diabetes and asymptomatic PAD. The objective was to determine
whether aspirin and antioxidant therapy, combined or alone, was more
effective than placebo in reducing cardiovascular events in patients with
diabetes and asymptomatic peripheral arterial disease.
This was a multicenter, randomized, double-blind, two by two, facto-
rial, placebo-controlled trial, It was conducted in 16 hospitals in Scotland
and involved 188 primary care groups. Entered into the trial were 1276
adults (aged40 years) with type 1 or type 2 diabetes and an ankle-brachial
index0.99, and no symptoms of cardiovascular disease. The daily regimen
was 100mg of aspirin plus antioxidant capsule in 320 patients, or aspirin plus
placebo in 318, or antioxidant plus placebo in 320, or two placebo capsules
in 318). The main outcome measures consisted of two composite primary
end points: (1) death from coronary heart disease or stroke, nonfatal
myocardial infarction or stroke, or amputation above the ankle, and (2) and
death from coronary heart disease or stroke.
There was no evidence of any benefit of aspirin or antioxidant therapy.
There were 638 primary events, of which 116 occurred in the aspirin groups
compared with 117 in the no-aspirin group (18.2% vs 18.3%; hazard ratio
[HR] 0.98, 95% confidence interval [CI], 0.76-1.26). There were 43 deaths
from coronary heart disease or stroke in the aspirin groups compared with 35
deaths in the no-aspirin groups (6.7% vs 5.5%; HR, 1.23, 95% CI, 0.79-
1.93). In the antioxidant groups, 117 primary events (18.3%) occurred;
whereas in the no-antioxidant therapy groups, 116 (18.2%) occurred (HR,
1.03; 95%CI, 0.79-1.33). There were 42 deaths from coronary heart disease
or stroke in the antioxidant groups compared with 36 deaths from coronary
heart disease or stroke in the no-antioxidant groups (6.6% vs 5.7%, respec-
tively; HR, 1.21; 95% CI, 0.78-1.89).
Comment: Once again, aspirin fails as primary preventative therapy in
patients with diabetes. This study extended that conclusion to patients with
asymptomatic PAD. The study, however, should not be construed as justi-
fication for failure to use aspirin as secondary preventative therapy in patients
with cardiovascular disease and diabetes. Aspirin may be a so-called wonder
drug, but it does not seem to be good for everything.
A Randomized Controlled Trial of Financial Incentives for Smoking
Cessation
Volpp KG, Troxel AB, Pauly MV, et al. N Engl J Med 2009;360:699-709.
Conclusions: Financial incentives for smoking cessation increase rates
of smoking cessation.
Summary: In the United States, there are 438,000 deaths each year
attributed to smoking. About 70% of smokers desire to quit, but only about
2% to 3% are able to succeed each year. Pharmacologic therapies and
smoking-cessation programs can produce higher rates of cessation of to-
bacco use; however, rates of participation in such programs are low. Previous
studies have evaluated financial incentives to induce smoking cessation but
have not shown significant increases in long-term cessation rates. The
authors postulate that the previous studies were limited by small sample sizes
and relatively weak financial incentives.
This trial recruited employees from a large multinational company
based in the United States. Financial incentives of up to $750 were tested for
their ability to improve long-term smoking cessation. A total of 878 em-
ployees received information about smoking-cessation programs. Of these,
436 were randomized to receive this information with financial incentives,
and 442 received no financial incentives. The financial incentives offered
were $100 for completion of a smoking-cessation program, and $250 for
cessation of smoking 6 months after study enrollment, with smoking
cessation confirmed by a biochemical test. Finally, $400 was offered for
abstinence for an additional 6 months after the initial cessation, again with
